Genitourinary Cancer Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY26318
NRG-GU013: THE PHASE III HIGH FIVE TRIAL FIVE FRACTION RADIATION FOR HIGH-RISK PROSTATE CANCER
To compare metastasis-free survival, determined using conventional imaging, between men with high-risk prostate cancer randomized to ultrahypofractionation (SBRT) to those randomized to moderate hypofractionation and conventional fractionation
Study InformationSTUDY26341
The WATER IV Prostate Cancer: Aquablation Therapy Versus Radical Prostatectomy for the Treatment of Localized Prostate Cancer
To evaluate the safety and efficacy of Aquablation Therapy with the AQUABEAM Robotic System and the HYDROS Robotic System to reduce treatment related harm in men with Grade Group (GG) 1 to 3 localized prostate cancer who are candidates for, or have selected, prostatectomy.
Study InformationSTUDY26541
Hypofractionated Radiotherapy with a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
To evaluate the incidence of CTCAE grade 2 or higher acute genitourinary (GU) toxicity.
Study InformationSTUDY26705
Short Term Intensified Pembrolizumab (Keytruda) And Tivozanib For High-Risk Renal Cell Carcinoma (STRIKE)
2.0 OBJECTIVES 2.1 Primary Objective To compare disease free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. 2.2 Secondary Objectives 2.2.1 To compare overall survival (OS) for patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. 2.2.2 To assess adverse events in each study arm by CTCAE 5.0.
Study InformationSTUDY27589
NRG-GU015: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)
Demonstrate non-inferiority of ultra-hypofractionated (SBRT) compared to hypofractionated RT with a 10% non-inferiority margin (from 50% to 40%) in the rate of bladder-intact event-free survival (BI-EFS) at 3 years (corresponding to a hazard ratio <1.32)
Study Information